source
- London biotech Oyster raises $60 million to develop tau-targeting protein degradersOyster Therapeutics, a London-based biotech, announced it has secured $60 million in an extension of its Series A financing round. The funding will support its lead program that uses a modified pr…
- Democrats demand unredacted drug pricing agreements from pharma firms after midterm victoriesCongressional Democrats have intensified scrutiny of pharmaceutical pricing agreements made under the previous administration. On Monday they sent letters to every drug maker that entered a most f…